14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AURA vs VIR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
VIR Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)
VIR Overall Winner
6-Pillar Tally: AURA 2 – 4 VIR
Matrix Metrics: AURA 4 – 6 VIR
As of Nov 16, 2026, Vir Biotechnology, Inc. (VIR) is the stronger overall head-to-head candidate over Aura Biosciences, Inc. (AURA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). AURA carries a Unified Composite Score of 28.8/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas VIR carries 41.6/100 (SELL) at $9.76 (4.3x Forward P/E, -70.2% operating margin).
Defensive Composite Rating Caution: Although VIR compares more favorably head-to-head, both AURA (28.8/100 SELL) and VIR (41.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.7); meanwhile VIR is in a Breakdown options structure phase (RSI 39.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AURA vs VIR. Trailing 12-month operating profitability (AURA 0.0% vs VIR -70.2%) and valuation multiples (AURA N/M vs VIR 4.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $728.6M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
VIR Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and -70.2% operating margin.
OpEx & R&D Reinvestment33.5% of Rev ($101M)
90D Engineering Disclosures0 Published
Investor FAQ AURA vs VIR Key Questions & Quantitative Answers
As of Nov 16, 2026, Vir Biotechnology, Inc. (VIR) is the stronger overall head-to-head candidate over Aura Biosciences, Inc. (AURA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). AURA carries a Unified Composite Score of 28.8/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas VIR carries 41.6/100 (SELL) at $9.76 (4.3x Forward P/E, -70.2% operating margin). Defensive Composite Rating Caution: Although VIR compares more favorably head-to-head, both AURA (28.8/100 SELL) and VIR (41.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.7); meanwhile VIR is in a Breakdown options structure phase (RSI 39.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VIR leads the Growth & Scale pillar: AURA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VIR at +19582.5% YoY revenue growth and +58.5% YoY earnings growth on $303M TTM revenue (-36.7% gross margin, -70.2% operating margin). On trailing 12-month operating scale, AURA generates N/A in USD-normalized revenue versus $303M for VIR. In operating R&D and SG&A reinvestment, AURA deploys N/A (0 90-day corporate R&D disclosures) versus 33.5% of Rev ($101M) (0 disclosures) for VIR.
VIR screens cheaper on headline valuation multiples. AURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VIR trades at 4.3x Forward P/E, 4.3x Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-46.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AURA (-61.7% ROE) versus VIR (-21.8% ROE) capital efficiency.
In options market volatility and institutional positioning, AURA carries 160.1% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 75% Vol realized risk). By comparison, VIR carries 69.6% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.20x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.71β · 102% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.